Podcasts about xantus

The United States and Japan are co-sponsoring a UN Security Council resolution that calls for a ban on any nuclear weapons in orbit. Benchmark Space Systems has successfully deployed its next-gen Xantus electric propulsion aboard Space Solutions' 12U cubesat in low Earth orbit.Terran Orbital's subsidiary Tyvak International has delivered the Hera Milani satellite to the European Space Agency, and more. Remember to leave us a 5-star rating and review in your favorite podcast app. Miss an episode? Sign-up for our weekly intelligence roundup, Signals and Space, and you'll never miss a beat. And be sure to follow T-Minus on LinkedIn and Instagram. T-Minus Guest Our guest today is Nick Searra, Executive Director of the Interstellar Foundation. You can connect with Nick on LinkedIn and learn more about the Interstellar Foundation on their website. Selected Reading US and Japan seek UN resolution calling on all nations to ban nuclear weapons in outer space- AP News A Suspicious Pattern Alarming the Ukrainian Military - The Atlantic Ready for take-off: A look inside the IDF's new Space Directorate Unit Press Release: Benchmark Electric Propulsion Thrusters On Orbit And Poised For First Fire Space Workforce 2030 Names New Executive Director in Landmark Partnership Spire Global to Enhance AI-Driven Weather Prediction in Collaboration with NVIDIA Terran Orbital's Milani Satellite Delivered to the European Space Agency for Hera Mission- Business Wire China building giant hypersonic railgun for space launches - Asia Times While USSF Budget Dips, Funds for New Nuclear Command and Control Satellites Jump 1st Space Brigade's tactical close space support is on the move Biden's tax proposals would hurt commercial space ESA - Operations begin to de-ice Euclid's vision T-Minus Crew Survey We want to hear from you! Please complete our 4 question survey. It'll help us get better and deliver you the most mission-critical space intel every day. Want to hear your company in the show? You too can reach the most influential leaders and operators in the industry. Here's our media kit. Contact us at space@n2k.com to request more info. Want to join us for an interview? Please send your pitch to space-editor@n2k.com and include your name, affiliation, and topic proposal. T-Minus is a production of N2K Networks, your source for strategic workforce intelligence. © N2K Networks, Inc. Learn more about your ad choices. Visit megaphone.fm/adchoices

Kim Eisenmann ist CEO und Mitgründerin der Twinvay GmbH. Sie hat es auf die Forbes Liste „30 under 30“ geschafft. Twinvay produziert und vertreibt Xantrus, ein K.O. Tropfen Schutz-Armband an. In dieser Episode spricht Franz Kubbillum mit Kim Eisenmann über die Gründung von Twinvay und das wichtige Thema der K.O.-Tropfen. Eisenmann erklärt das Funktionsprinzip des K.O. Tropfen-Schutzarmbands und erzählt wie sie und ihre Mitgründer auf die Idee kamen. Sie beschreibt Szenarien, in denen K.O.-Tropfen eingesetzt werden, und betont, dass es sich dabei nicht nur um Party-Situationen handelt. Außerdem spricht sie über die Motive, weshalb K.O. Tropfen verabreicht werden, und die Folgen, die dadurch entstehen. Nach ihrem Schulabschluss absolvierte Eisenmann gleichzeitig ihren Bachelor- und Master-Abschluss in Wirtschaftsingenieurwesen am Karlsruhe Institute of Technology (KIT). Zur selben Zeit gründete sie gemeinsam mit ihrem Verlobten das Start-up Twinvay und arbeitete nebenbei. Wie hat sie all das unter einen Hut gebracht? Die beiden bauten das Start-up ohne externe Investoren auf und brachten das Produkt mit dm als Launch-Partner erstmals auf den deutschen Markt. Weshalb haben sich die beiden gegen Investoren entschieden? Aber das ist noch nicht alles: Neben ihrer Tätigkeit als CEO bei Twinvay gründen die beiden eine US-Firma, sind Investoren in den Bereichen Edelmetalle und NFTs/Krypto und schreiben Kinderbücher. Wie findet Eisenmann einen Ausgleich zu ihrem Alltag und welche Tipps hat sie, um ihren Alltag effizient zu gestalten? Schließlich gibt sie Einblicke in die besondere Unternehmenskultur bei Twinvay und die besonderen Managementstrategien. Themen - Gründen während des Studiums - K.O. Tropfen - Gründen ohne Investoren - Strategien für eine effiziente Alltags-Gestaltung - Relevanz des richtigen Freundeskreises - Ausgleich schaffen ------ Über Atreus – A Heidrick & Struggles Company Atreus garantiert die perfekte Interim-Ressource (m/w/d) für Missionen, die nur eine einzige Option erlauben: nachhaltigen Erfolg! Unser globales Netzwerk aus erfahrenen Managern auf Zeit zählt weltweit zu den besten. In engem Schulterschluss mit den Atreus Direktoren setzen unsere Interim Manager vor Ort Kräfte frei, die Ihr Unternehmen zukunftssicher auf das nächste Level katapultieren. ▶️ Besuchen Sie unsere Website: https://www.atreus.de/ ▶️ Interim Management: https://www.atreus.de/kompetenzen/service/interim-management/ ▶️ Für Interim Manager: https://www.atreus.de/interim-manager/ ▶️ LinkedIn-Profil von Kim Eisenmann: https://www.linkedin.com/in/kim-eisenmann-431743120/ ▶️Webseite des Xantus Drinkcheck Armbands: https://www.xantus-drinkcheck.de/ ▶️ Profil von Franz Kubbillum: https://www.atreus.de/team/franz-kubbillum/ ▶️ Behind the C auf Instagram: https://www.instagram.com/behindthecpodcast/

Steve is the Executive Chair of Mason Advisory a leading specialist focusing on digital and tech advisory to Private & Public Sector Clients. Steve has founded two successful firms and sold one, and has had a 30 year career in the IT and Management Consulting space. The first firm Steve founded, Xantus, a specialist digital and tech consultancy, was sold to KPMG in October 2011.https://www.masonadvisory.com/Prof. Joe O'Mahoney helps boutique consultancies scale and exit. Joe's research, writing, speaking and insights can be found at www.joeomahoney.com

Aki szeretné, hogy a huszadik születésnapunkra meglegyen a 200 Patreon támogatónk, az ide jöjjön! ........................... Breaking! Xantus Barbara jól van! Sajnos lapzártakor még nem hozzáférhető a Spagetti lakóautó 24 órás adásának felvétele. Iratkozz fel, hogy ne maradj le róla. Karl May mint Old Shatterhand. Xántus János levelei Éjszakamerikából. A Henry karabély (puska). Amerikai hallgatóink vehetnek is! A Magyar volt-e Old Shatterhand c. dokumentumfilm, aminek a forgatókönyvét Xantus János filmrendező írta. Xantus János 2001-es dokumentumfilmje a Tilos Rádióról, amikor a most szombat éjfélhez hasonlóan elfogyott a freki. Adászene: LGT. A borítóképen Xantus János. ........................... Ha szeretnél támogatni minket, a Patreon oldalunkon megteheted. A gombapresszó Twitter csatornája. Az élő adások helyszine, az MR4 csatorna. Az adászenéket tartalmazó Spotify lista.

This podcast is a follow-up to Bayer's symposium at ESC 2022, ‘The beginning of the end for NOACs? The extra mile'. In this episode, Dr Manesh Patel and Professor Rupert Bauersachs expand on the discussions from the symposium, providing further insight into the management of frail patients with AF and VTE. The experts also provide their perspectives on the treatment of paediatric patients with VTE and patients with cancer-associated thrombosis, evaluating the available evidence to guide decision-making for these particularly vulnerable patients. The views and opinions expressed throughout this podcast are those of the speakers based on their expertise and do not necessarily reflect those of Bayer. Further details: • The EINSTEIN programme publications can be found here for EINSTEIN PE (https://www.nejm.org/doi/full/10.1056/NEJMoa1113572), EINSTEIN DVT (https://www.nejm.org/doi/full/10.1056/NEJMoa1007903), EINSTEIN Pooled (https://thrombosisjournal.biomedcentral.com/articles/10.1186/1477-9560-11-21), EINSTEIN CHOICE (https://www.nejm.org/doi/full/10.1056/nejmoa1700518) and EINSTEIN JUNIOR (https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(19)30219-4/fulltext) • Real-world evidence published by Craig Coleman on the efficacy and safety of rivaroxaban versus warfarin in frail patients with VTE can be accessed here: https://www.amjmed.com/article/S0002-9343(18)30202-X/fulltext • The XALIA study publication can be found here: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(15)00257-4/fulltext • The findings from the XANTUS trial are available here: https://academic.oup.com/eurheartj/article/37/14/1145/2466063 • Access the ROCKET AF manuscript here: https://www.nejm.org/doi/full/10.1056/nejmoa1009638 • The elderly subgroup analysis of ROCKET AF can be found here: https://www.ahajournals.org/doi/10.1161/circulationaha.113.005008 • Findings from the SAFIR trial can be accessed here: https://heart.bmj.com/content/107/17/1376 • Find the edoxaban phase II trial paper here: https://www.thieme-connect.com/products/ejournals/abstract/10.1160/TH10-01-0066 • Read the SELECT-D study paper here: https://ascopubs.org/doi/10.1200/JCO.2018.78.8034 • Information on the OSCAR trials can be found here for the UK (https://clinicaltrials.gov/ct2/show/NCT05112666, https://abstracts.isth.org/abstract/comparison-of-effectiveness-and-safety-of-direct-oral-anticoagulant-versus-low-molecular-weight-heparin-treatment-for-venous-thromboembolism-in-patients-with-active-cancer-the-oscar-uk-study/) and the US (https://clinicaltrials.gov/ct2/show/NCT04979780, https://www.sciencedirect.com/science/article/pii/S0006497121040908) • Details on the Mayo Clinic prospective cohort study are available here: https://www.mayoclinicproceedings.org/article/S0025-6196(21)00435-3/fulltext • Support for the proportion of patients not receiving anticoagulation can be accessed here: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278389/#CIT0011 • For anticoagulant dosing information, see the European labels for apixaban (http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf), dabigatran (http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf), edoxaban (http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002629/WC500189045.pdf), rivaroxaban (https://www.ema.europa.eu/documents/product-information/xarelto-epar-product-information_en.pdf) and warfarin (https://www.medicines.org.uk/emc/product/3064/smpc) Audio: MA-M_RIV-ALL-1236-1 Shownotes: MA-M_RIV-ALL-1237-1

Aki szeretné, hogy a huszadik születésnapunkra meglegyen a 200 Patreon támogatónk, az ide jöjjön! ........................... Breaking! Xantus Barbara jól van! Sajnos lapzártakor még nem hozzáférhető a Spagetti lakóautó 24 órás adásának felvétele. Iratkozz fel, hogy ne maradj le róla. Karl May mint Old Shatterhand. Xántus János levelei Éjszakamerikából. A Henry karabély (puska). Amerikai hallgatóink vehetnek is! A Magyar volt-e Old Shatterhand c. dokumentumfilm, aminek a forgatókönyvét Xantus János filmrendező írta. Xantus János 2001-es dokumentumfilmje a Tilos Rádióról, amikor a most szombat éjfélhez hasonlóan elfogyott a freki. Adászene: LGT. A borítóképen Xantus János. ........................... Ha szeretnél támogatni minket, a Patreon oldalunkon megteheted. A gombapresszó Twitter csatornája. Az élő adások helyszine, az MR4 csatorna. Az adászenéket tartalmazó Spotify lista.

This podcast is a follow up to Bayer's symposium at ESC 2021 ‘Evolving Cardiovascular Risk: Your Patient's Past, Present and Future'. Following on from the discussions at that meeting, Professor Craig Coleman and Professor Roxana Mehran provide further expert perspectives on the importance of considering your patient's kidney function when they have atrial fibrillation, and discuss how to protect patients from the devastating effects of stroke. Professor Manesh Patel and Dr Rónán Collins then focus on stroke prevention in older patients with atrial fibrillation and highlight the fascinating studies that caught their eye among the ESC scientific programme. Further details: • Read the 2020 ESC guidelines for the management of atrial fibrillation here: https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Atrial-Fibrillation-Management • Find the 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation here: https://www.ahajournals.org/doi/10.1161/CIR.0000000000000665 • The EHRA practical guide on the use of NOACs in patients with atrial fibrillation can be accessed here: https://academic.oup.com/europace/article/23/10/1612/6247378 • Real-world evidence from the ANTENNA study showing the benefit of rivaroxaban versus warfarin for the treatment of renal decline in patients with atrial fibrillation is available here: https://esc2021-abstract.medicalcongress.online/mediatheque/media.aspx?channel=103467&mediaId=104597 • The study by Bonand et al. demonstrating the benefits of NOACs versus vitamin-K antagonists in patients older than 80 years with atrial fibrillation can be seen here: https://esc2021-abstract.medicalcongress.online/mediatheque/media.aspx?channel=103467&mediaId=107076 • Data from the EMIR study regarding treatment of elderly patients with atrial fibrillation with rivaroxaban can be seen here: https://esc2021-abstract.medicalcongress.online/mediatheque/media.aspx?channel=103467&mediaId=107122 • The study by Lee et al. confirming the positive net clinical benefits of NOACs in elderly patients with high bleeding risk and atrial fibrillation is available here: https://esc2021-abstract.medicalcongress.online/mediatheque/media.aspx?channel=103467&mediaId=104607 • Data presented by Chao et al. on the impact of off-label dosing of NOACs in elderly patients can be found here: https://esc2021-abstract.medicalcongress.online/mediatheque/media.aspx?channel=103467&mediaId=105312 • Data from the ETNA-AF study can be accessed here: https://esc2021-abstract.medicalcongress.online/mediatheque/media.aspx?channel=103467&mediaId=105275 • The original publication of the ARISTOTLE trial can be found here: https://www.nejm.org/doi/full/10.1056/nejmoa1107039 • Access to the ROCKET AF original publication can be found here: https://www.nejm.org/doi/full/10.1056/nejmoa1009638 • The XANTUS primary publication can be found here: https://academic.oup.com/eurheartj/article/37/14/1145/2466063 • For anticoagulant dosing information, see the European labels for apixaban (http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf), dabigatran (http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf), edoxaban (http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002629/WC500189045.pdf), rivaroxaban (https://www.ema.europa.eu/documents/product-information/xarelto-epar-product-information_en.pdf) and warfarin (https://www.medicines.org.uk/emc/product/3064/smpc) Show notes: MA-M_RIV-ALL-1126-1 Recording: MA-M_RIV-ALL-1125-1

Az elmúlt két év a búcsú éve volt, elbúcsúzott a munkahelyétől, a Turay Ida Színháztól, és elbúcsúzott a szerelmétől is. Ezekről mesél most a színésznő.

Az elmúlt két év a búcsú éve volt, elbúcsúzott a munkahelyétől, a Turay Ida Színháztól, és elbúcsúzott a szerelmétől is. Ezekről mesél most a színésznő.

.

For exclusive live interviews, every Wednesday follow us on Instagram at www.instagram.com/skyylevelmedia! DM us on who you want to see next on our show! Hosted by: @TheeBonnieBanks Produced by: @Niya_Skyy and @FromEmma J --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

Seit vielen Jahren sind KO-Tropfen eine konstante Bedrohung in der Partyszene. Viele Menschen haben Vorfälle im Familien und Bekanntenkreis hautnah miterlebt. So auch Kim Eisenmann und Sven Häuser, die Gründer des Start-Ups Xantus. Nachdem eine gute Bekannte von ihnen auf einem Fest KO-Tropfen verabreicht wurden, hat sich das junge Paar nach einer Lösung für dieses Problem umgesehen und anschließend ein Schnelltest-Armband für KO-Tropfen entwickelt. Wie sie dabei vorgegangen sind und wie sie es geschafft haben, mit dem Produkt in den Regalen von der Drogeriekette dm zu landen, erzählt Sven Häuser hier im Interview. Podcast Webseite: www.innovation-alchemist.com Xantus Drinkcheck: www.xantus-drinkcheck.de Xantus auf Instagram: www.instagram.com/xantus_drinkcheck Innovation Alchemist auf Instagram: www.instagram.com/innovationalchemist Felix Kranert auf LinkedIn: www.linkedin.com/in/felixkranert Feedback: feedback@innovation-alchemist.com

Dreams were just improv shows for the first few millennia. Then the writers got involved.   Written by Nick Douglas and Tim Mucci Featuring: Serena Berman as Bilquis and Claire Natalie Walker as Yolf and Bea Nicholas Douglas as Jasher Timothy Mucci as Photini Jordan Smith as Xantus of the Crimson Eye Liz Leimkuhler as Lizathee   Editing, sound design, and mixing by Levi Sharpe Theme by Jason Oberholtzer Outro music by SYBS Cover art by Andrea Sparacio   Dark web: roommatefromhell.rip Email: roommatefromhellshow@gmail.com Twitter: @evilsitcom IG: @evilsitcom

Find our about the Xantus Hummingbird in today's A to Z of Wildlife. See omnystudio.com/listener for privacy information.

Lagunitas taproom, goses, gueuzes, and summer vacations.

Lagunitas taproom, goses, gueuzes, and summer vacations.

Special Guest: Nik White. Nik talks with us about Chicago Beer Geeks, The new Chicago Beer Pass Podcast, and we finally taste the Beard Beer!

Special Guest: Nik White. Nik talks with us about Chicago Beer Geeks, The new Chicago Beer Pass Podcast, and we finally taste the Beard Beer!

Decade episode recap. Plan for the end of the BeerDownload tournament? Fobab planning.

Decade episode recap. Plan for the end of the BeerDownload tournament? Fobab planning.

Recitation of letter from Freetail Brewing. Correction of ORD. Paul Schneider at Chitown On Tap's list of upcoming Chicago breweries. Alchemy and Science acquires Angel City Brewing in L.A.

Recitation of letter from Freetail Brewing. Correction of ORD. Paul Schneider at Chitown On Tap's list of upcoming Chicago breweries. Alchemy and Science acquires Angel City Brewing in L.A.

Deuces - Chris Brown Deuces (freestyle) - Josh Xantus  Josh Xantus Interview I Don't Care featuring Ghostface - Josh Xantus Josh Xantus Interview B  Love The Way - Josh Xantus Let's Ride featuring Jadakiss - Josh Xantus First Time - Josh Xantus The One (freestyle) - Josh Xantus **HOT Keep It Poppin featuring Vado, Jae Millz - Verse Simmonds Looking For Love featuring Usher - Rick Ross The Show Goes On - Lupe Fiasco   Love Ultra - Tuesday Night R&B Mix Show heard 11pm to 1am heard on www.DaFlavaRadio.com and podcast archived on http://JahPrince.Podomatic.com

  Fall In Love (Your Funeral) - Erykah BaduSupaStar feat. Common - FloetryI Don’t Care feat. Ghostface - JoSh X Broke My Heart - Nikki GrierI Need Some Help - Nikki GrierDowntown - Nikki Grier ft. Busta Rhymes Nikki Grier Interview Love I Found feat. Anthony Hamilton - Nikki Grier Even Angels - FantasiaLove King f. Jeezy (rmx) - DreamFew Reasons (Truth Pt. 2) - Dwele Love Ultra - Tuesday Night R&B Mix Show heard 11pm to 1am heard on www.DaFlavaRadio.com and podcast archived on http://JahPrince.Podomatic.com

Crazy Love feat. Fabolous - Ne-YoWorkin' On It - DweleBroke My Heart - Nikki GrierThe Bee Remix - Jessica Tonder ft. ProtonI Don't Care feat. Ghostface - Josh XantusGood Love - Nikki Grier ft. Ms. Jade5 Seconds feat Fabolous - El DebargeShady - DweleGet Busy - The RootsHigher feat. Poodie The Byz - Adrift Da BelleLet Me Love You (Remix) ft. T.I. & Jadakiss - Mario*Make Me A Fool - The Foreign ExchangeThis Song Is for You - J. Tait

Change - Faith Evans Way You Move - Faith Evans feat Snoop Dogg Somehting That I Like - Ryan Leslie feat Pusha T All I Want Is - Miguel Jontel ft J Cole & Raekwon Let's Ride - Josh Xantus feat Jadakiss Holding You Down (remix) - Jazmine Sullivan, Mary J Blige, Swizz Beatz I Don't Care - Josh Xantus feat Ghostface I'm Ill (remix) - Red Cafe, Ryan Leslie I Think Its Over - Ne-Yo Runaway - Slick&Rose   FACE OFF 2nd Fridays at MJQ - @faceofffridays 736 Ponce de Leon Place NE, Atlanta, GA 3030 Love Ultra - Tuesday New RnB Music Mix Show 11pm - 1am Sunsplash Mix Show - Saturday Reggae & Dancehall Mix Show 10 am - 1pm